**Reviewer’s Comments**



**CELIAC DISEASE AMONG GASTROINTESTINAL PATIENTS IN YEMEN: ITS PREVALENCE IN GASTROINTESTINAL PATIENTS, SYMPTOMS AND ACCOMPANYING SIGNS; AND ITS PREVALENCE AMONG DIFFERENT AGES AND SEXES**

**ABSTRACT**

**Background and objectives**: Coeliac disease, or celiac disease (CD), is a long-term autoimmune disorder that primarily affects the small intestine. Classic symptoms include digestive problems such as chronic diarrhea, flatulence, malabsorption, loss of appetite, and failure of children to grow normally. The prevalence of celiac disease has not been established in Yemen, either in the general population or in symptomatic patients. Therefore, the current study aimed to assess the prevalence of disease in symptomatic patients and to investigate associated symptoms and signs; and whether prevalence of CD varies greatly between different ages and genders. **Methods:**A retrospective study based on the results of serological markers; IgA anti-tissue glutaminase and small bowel biopsies of 600 patients with gastrointestinal symptoms. Age, gender, clinical symptoms and co-morbidities were also considered and analyzed. Data were collected from hospital records during the period from March 2014 to December 2018. 600 suspected patients (245 males and 355 females) were subjects and the mean age of ± SD patients was 30.6 ± 14.5 years (range 2-92 years). **Results:** The prevalence of celiac disease among patients with gastrointestinal symptoms was 9.2%. There was a significant association between CD with females (rate being 11.3% , OR=1.9, p = 0.03), and 2-19 years age group (21.4% , odds ratio=4.3,p < 0.001), Considering the clinical signs and symptoms there was a significant association between celiac disease and chronic diarrhea (odds ratio = 18.4 times), steatorrhea ( OR = 9.6), foul odor (odds ratio = 8.3 times), weight loss ( Odds ratio = 5.7 times), anemia (odds ratio = 10.2 times), abdominal distension (odds ratio = 3.1 times), mouth ulcers (odds ratio = 7.2 times), abdominal bleeding (odds ratio = 13.5 times), diabetes mellitus I (odds ratio = 18 times), and hypothyroidism (odds ratio = 79.3 times). **Conclusion:** A high rate of celiac disease was identified among gastrointestinal symptoms patients arriving at the general hospital in Sana’a, Yemen, and this demonstrates the importance of general practitioners in identifying patients with celiac disease, especially in the absence of a medical facility for celiac disease, and this was facilitated through the EmA test. Our findings also indicate that celiac disease is more common in females, children and younger people, and there was an association between Celiac disease and the classic symptoms of this disease mentioned in the medical literature.

***Key words:*** Celiac disease, signs, symptoms, prevalence, Yemen

**INTRODUCTION**

Celiac disease or Coeliac disease (CD), is a continuing autoimmune illness that mainly involves the small intestine. Classic symptoms comprise digestive problems for instance chronic diarrhea, flatulence, malabsorption, loss of appetite, and failure of children to grow normally. This regularly begins between six months and two years of age. Non-classical symptoms are more frequent, in particular in people older than 2 years. There may be moderate or absent gastrointestinal symptoms, a large number of symptoms relating any part of the body, or no apparent symptoms. Celiac disease was first illustrated in childhood; nevertheless, it may arise at all ages. It is linked with autoimmune diseases, for instance type 1 diabetes and Hashimoto's thyroiditis1.Celiac disease results from a reaction with gluten, which is a group of different proteins found in wheat and other grains such as barley and rye. Moderate amounts of oats, free from pollution with further gluten-containing grains, are regularly tolerated2. The incidence of harms may depend on the type of oats. Celiac disease appears in people with a genetic predisposition. Upon exposure to gluten, the abnormal immune response may result in the production of many different autoantibodies that can involve a number of distinct organs. In the small intestine, this causes an inflammatory reaction and may lead to villous atrophy. This affects the absorption of nutrients, often leading to anemia3.The gold standards in diagnosing celiac disease are bowel biopsy and positive serological markers (anti-tissue IgA (Ttg IgA) antibody and anti-endomysial)1. HLA class II DQ2 and DQ8 haplotypes are found in nearly all patients with a sensitivity of nearly 100% and also in 30% to 40% of the population. On the basis of a very high negative predictive value, HLA typing can assist and support the exclusion of the diagnosis of celiac diseases in ambiguous cases in which the patient not have HLA-DQ2 and DQ84. On the other hand, making the diagnosis is not continuously simple5. Often, serum autoantibodies are negative, 4 and many people have only minor changes in the intestine with normal villi. People may have severe symptoms and may be explored for years before a diagnosis is made7. Currently, the diagnosis is increasingly being made in people who have no symptoms as a result of screening. However, the evidence regarding the effects of screening is not sufficient to determine its usefulness. While this disease is caused by a persistent intolerance to gluten proteins, 3 it differs from wheat allergy which is known to be very rare.

Epidemiologically, celiac diseaseaffects about 1 in 100 to 1 in 300 of the world's population1. This rate may be increased among those at risk; Like first-degree relatives: 1 in 10, or like second-degree relatives: 1 in 39 and 1 in 56 in asymptomatic patients 1. Moreover, the prevalence of celiac disease among unexplained iron deficiency anemia’s is 3% to 15%, 2% to 15% among type 1 diabetes, 2% to 7% among hypothyroidism, 3% to 6% among Addison's disease , and autoimmune hepatitis, 3% among irritable bowel syndrome, ataxia, and idiopathic neuropathy1. Studies in gastroenterology and/or autoimmune diseases are still limited in Yemen and only a few studies have been conducted on autoimmune hepatitis 9,10, and the relationship between CD and infertility by measuring sex hormones in CD compared to controls healthy 11, anti-mannose auto-antibodies in patients with rheumatoid arthritis 12, and intestinal infection among adults and children13-15. The prevalence of celiac disease has not been established in Yemen, either in the general population or in symptomatic patients. Therefore, the current study aimed to assess the prevalence of disease in symptomatic patients and to investigate associated symptoms and signs; and whether prevalence of CD varies greatly between different ages and genders.

**MATERIALS AND METHODS**

**STUDY DESIGN AND SETTING**

study was conducted at the University of Science and Technology Hospital (USTH) in Sana'a, Yemen. USTH is one of the main hospitals in Yemen, which receives patients from all over the country and also the city of Sana'a is the capital of Yemen. For these factors, the results of this study may represent the whole country.

**DATA COLLECTION**

600 symptomatic patients were enrolled in this study. Among them, 245 (40.8%) males and 355 (59.2%) females attended pediatric clinics, internal medicine clinics, and gastroenterology units for medical care in USTH from March 2014 to December 2018. Data were obtained from electronic patient records after approval of the hospital ethics committee. By enzyme-linked immunosorbent assay (ELISA), positive ATtg IgA criteria greater than 10 times the ULN in children or less than 10 times the ULN but confirmed by small bowel biopsy, were the criteria used to measure the prevalence of celiac disease. Hemoglobin levels (to define anemia based on a hemoglobin concentration less than 11 g/dL) were also included. The subjects were divided into categories based on gender and age. Clinical signs, symptoms and other diseases associated with celiac disease were also collected and analyzed.

**DATA ANALYSIS**

The whole data were analyzed by IBM SPSS Statistics 22.Ink (International Business Machines Corporation, New York, USA). The outcomes for variables were given in the form of rates (%). Chi Square was used for categorical variables that measured association among categorical variables. *P*-values less than 0.05 were considered significant. Odds of celiac disease (odds ratio, OR) were also analyzed by sex, age groups, symptoms, signs and other syndromes, with 95% *CI, X2* and *p* to test for significance of association with the above factors.

**RESULTS**

Table 1 shows the age and gender distribution of patients with gastrointestinal symptoms admitted to the University of Science and Technology Hospital, Sana'a, Yemen - during the period from March 2014 to December 2018 who underwent examination for serological markers; Anti-tissue IgA glutaminase and small intestine biopsies for celiac disease. The percentage of females was 59.2% compared to 40.8% for males. Looking at the age groups, most patients were in the age group 20-40 years (58.2%), followed by 2-19 years (21%) and 41-60 years (18%), while the >60 years group was only 2.8%. Table 2 shows the prevalence of serological markers. Anti-tissue IgA glutaminase and small bowel biopsies for celiac disease among different sex and age groups of patients with gastrointestinal symptoms. The prevalence of celiac disease among patients with gastrointestinal symptoms was 9.2%. Considering gender, there was a significant association between celiac disease and females with the rate being 11.3% with an odds ratio equal to 1.9, CI equal to 1.1–3.9 (p = 0.03). Considering ages, there was a significant association between celiac disease with 2-19 years as the rate was 21.4% with an odds ratio equal to 4.3, CI equal to 2.4-7.6 (p < 0.001), while there was no association between celiac disease and age groups other. Considering the clinical signs and symptoms associated with intestinal symptoms compared to celiac disease (Table 3), there was a significant association between celiac disease and chronic diarrhea (odds ratio = 18.4 times), steatorrhea (OR = 9.6), foul odor (odds ratio = 8.3 times), weight loss (Odds ratio = 5.7 times), anemia (odds ratio = 10.2 times), abdominal distension (odds ratio = 3.1 times), mouth ulcers (odds ratio = 7.2 times), abdominal bleeding (odds ratio = 13.5 times), diabetes mellitus I (odds ratio = 18 times), and hypothyroidism (odds ratio = 79.3 times).

**DISCUSSION**

Celiac disease is an immune condition mediated by systemic disease of the small intestine Symptoms related to malabsorption and/or activation of immunity and autoantibodies to tissue transglutaminase (TTG). Celiac disease is distinctive amongst autoimmune diseases in that a generate, dietary gluten, has been recognized, and its removal resolves symptoms and enteropathy in the greater part of patients. Increased awareness and development of serological tests have led to an increased incidence of disease and a change in the distribution of clinical features1 .In Yemen, its prevalence has not yet been estimated, and current work is an attempt to determine the rate of CD among clinically suspected patients.The prevalence of celiac disease among patients with gastrointestinal symptoms in the current study was 9.2%. Compared with our observations, the prevalence of CD in Yemen exceeds the rate of CD among suspected Finns 5.33% among patients with gastrointestinal symptoms16 and other previous rates of disease as in Saudi Arabia, South Yorkshire, Amsterdam, the Netherlands and in North America are among the symptoms gastrointestinal representing; 7.6%, 4.7%, 3.0% and 2.0%, respectively17-20.On the other hand, results similar to ours were presented by Dickey *et al* and Hopper *et al*21,22 where the incidence of celiac disease among patients with undiagnosed gastrointestinal symptoms was about 9%. In contrast to the average (9.2%), the prevalence of CD among Iranian patients with irritable bowel syndrome was about 12% and among patients with gastrointestinal symptoms in Italy was about 13% as reported by Shahbazkhani*et al* and Carroccio*et al*respectively23,24.Considering gender, there was a significant association between celiac disease and females with a rate of 11.3% (OR = 1.9 (CI = 1.1-3.9, p = 0.03) (Table 2). This result is similar to that reported where the incidence of celiac disease is higher in females than in males (17.0 versus 7.8 per 100,000 person-years) in pooled analysis25,but this may be because men are more likely to remain undiagnosed. A systematic review and meta-analysis found a slight increase in seropositivity among women participating in screening studies 26 although some studies in adults have found that men and women have the same seroprevalence rates27,28. Men are less likely to undergo duodenal biopsy during upper endoscopy for indications such as diarrhea and weight loss, which may contribute to underdiagnosis29.Celiac disease can develop at any age, including the elderly 30. Considering age in the current study, there was a significant association between celiac disease and age group 2-19 years where the rate was 21.4% with an odds ratio equal to 4.3, CI equal to 2.4-7.6 (p < 0.001) (Table 2). This is similar to what has been previously reported where the incidence of CD was higher in the younger age group. This rise in CD at a young age can be explained by the fact that such diagnoses do not necessarily indicate the late detection of celiac disease long ago - it may result from a de novo loss of gluten tolerance. Studies of serial serum samples have reported loss of gluten tolerance in adulthood31.However, recent prospective cohort studies have found that most patients develop celiac disease before the age of 10 years32,33.Moreover, in our study, the prevalence of anemia was widespread (71.4%, OR = 40.4 times, P<0.001) (Table 3) among ATtg IgA-positive patients in agreement with several studies34, 35. These patients are more likely to have acute disease compared to non-anaemic CD patients according to Daya, *et al*36.

Once serological testing began in the 1990s, there was an expansion of clinical offerings leading to a diagnosis of celiac disease. The proportion of patients with celiac disease who had diarrhea decreased from 73% before 1993 (the year in which serological testing became available at the study site) to 43% thereafter 37. Although diarrhea continued to be the most common symptom at presentation, most patients received the diagnosis based on this on other signs or symptoms, such as osteoporosis, anemia, bloating, or irregular bowel habits; some had less common symptoms, including infertility9, migraine headaches 38 neuropsychiatric symptoms39 and abnormal liver enzyme levels40.

In the current study considering the clinical signs and symptoms associated with intestinal symptoms compared to celiac disease, there was a significant association between celiac disease and chronic diarrhea (odds ratio = 18.4 times), steatorrhea ( OR = 9.6), foul odor (odds ratio = 8.3 times), weight loss ( Odds ratio = 5.7 times), anemia (odds ratio = 40.4 times), abdominal distension (odds ratio = 3.1 times), mouth ulcers (odds ratio = 7.2 times), abdominal bleeding (odds ratio = 13.5 times), diabetes mellitus I (odds ratio = 18 times), and hypothyroidism (odds ratio = 79.3 times). These signs and symptoms combined outnumber diarrhea, so diarrhea can no longer be referred to as typical and presentation without diarrhea as atypical. As such, a 2013 consensus statement renamed diarrhea and non-diarrhea presentations as classic and non-classical celiac disease, respectively41. Regardless of the type of symptoms, there is often a long-term delay between the onset of symptoms and a diagnosis of celiac disease. A national survey of patients with celiac disease in the US found the median duration of symptoms to be 11 years before diagnosis 42 and a UK study found the median duration to be 4.9 years43.In the current study, abnormal LFT occurred in 20% of CD patients, and this is lower than that performed by Castillo *et al.* as liver biochemical abnormalities were presented in 40% of patients newly diagnosed with celiac disease, according toCastillo *et al.*series the slight increases observed in aspartate and alanine transaminases are the most common abnormalities 40.The incidence of celiac disease is increasing with its worldwide spread. There is a trend towards an increased diagnosis of non-classical presentations, and there is emerging evidence for accurate non-biopsy diagnosis in selected children32.Newly developed diagnostic tools, such as the HLA-DQ-based blood test - gluten tetramer, may change the way we diagnose celiac disease in the near upcoming, impending validation and scalability. This technique, combined with validation of serology-based diagnostic algorithms, may lead to a change in diagnostic criteria as a small bowel biopsy is no longer necessary while patients continue to follow a gluten-containing diet. These changes may transform the roles of gastroenterologists, from diagnosis to management and follow-up. If an evidence-based, biopsy-free strategy is developed for diagnosis, the incidence of celiac disease may increase further and stimulate interventional studies to prevent celiac disease in at-risk individuals 1.

**CONCLUSIONS**

The prevalence of CD among Yemeni patients with gastrointestinal disorders was as high as 9.2%, especially among children and adolescents. The disease was prevalent among females. On the other hand diagnosis by serological markers is useful in detecting CD in these patients. However, more studies are needed to support and confirm our findings and conclusions. According to this high prevalence, clinicians should pay more attention to CD when examining huge different symptoms especially among women, children and teens to avoid misdiagnosis or long-term delay diagnosis.

**ACKNOWLEDGMENTS**

The authors acknowledge the administration of University of Science and Technology Hospital for data supply.

**AUTHORS’ CONTRIBUTIONS**

All authors contributed to the study design, analysis and manuscript writing.

**ETHICAL APPROVAL**

Ethical approval was obtained from the Ethics Committee from the USTH Sana'a, Yemen.

**REFERENCES**

1- Lebwohl B and Rubio-Tapia A. Epidemiology, Presentation, and Diagnosis of Celiac Disease. Gastroenterology 2021;160:63–75. <https://doi.org/10.1053/j.gastro.2020.06.098>

2- Pinto-Sánchez MI, Causada-Calo N, Bercik P, Ford AC, Murray JA, Armstrong D, Semrad C, Kupfer SS, Alaedini A, Moayyedi P, Leffler DA, Verdú EF, Green P (August 2017). ["Safety of Adding Oats to a Gluten-Free Diet for Patients With Celiac Disease: Systematic Review and Meta-analysis of Clinical and Observational Studies"](http://eprints.whiterose.ac.uk/115341/1/FordSafety%20of%20Adding%20Oats.pdf) (PDF). Gastroenterology. **153** (2): 395–409.e3. [doi](https://en.wikipedia.org/wiki/Doi_%28identifier%29%22%20%5Co%20%22Doi%20%28identifier%29):[10.1053/j.gastro.2017.04.009](https://doi.org/10.1053/j.gastro.2017.04.009). [PMID](https://en.wikipedia.org/wiki/PMID_%28identifier%29%22%20%5Co%20%22PMID%20%28identifier%29) [28431885](https://pubmed.ncbi.nlm.nih.gov/28431885).

3- Tovoli F, Masi C, Guidetti E, Negrini G, Paterini P, Bolondi L. ["Clinical and diagnostic aspects of gluten related disorders"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360499). World Journal of Clinical Cases  2015; **3** (3): 275-84.  [doi](https://en.wikipedia.org/wiki/Doi_%28identifier%29%22%20%5Co%20%22Doi%20%28identifier%29):[10.12998/wjcc.v3.i3.275](https://doi.org/10.12998/wjcc.v3.i3.275). [PMC](https://en.wikipedia.org/wiki/PMC_%28identifier%29%22%20%5Co%20%22PMC%20%28identifier%29) [4360499](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360499). [PMID](https://en.wikipedia.org/wiki/PMID_%28identifier%29%22%20%5Co%20%22PMID%20%28identifier%29) [25789300](https://pubmed.ncbi.nlm.nih.gov/25789300).

4- Lewis NR, Scott BB. ["Systematic review: the use of serology to exclude or diagnose coeliac disease (a comparison of the endomysial and tissue transglutaminase antibody tests)"](https://doi.org/10.1111/j.1365-2036.2006.02967.x). Alimentary Pharmacology & Therapeutics 2006;  **24** (1): 47–54. [doi](https://en.wikipedia.org/wiki/Doi_%28identifier%29%22%20%5Co%20%22Doi%20%28identifier%29):[10.1111/j.1365-2036.2006.02967.x](https://doi.org/10.1111/j.1365-2036.2006.02967.x). [PMID](https://en.wikipedia.org/wiki/PMID_%28identifier%29%22%20%5Co%20%22PMID%20%28identifier%29) [16803602](https://pubmed.ncbi.nlm.nih.gov/16803602). [S2CID](https://en.wikipedia.org/wiki/S2CID_%28identifier%29%22%20%5Co%20%22S2CID%20%28identifier%29) [16823218](https://api.semanticscholar.org/CorpusID%3A16823218).

5- Matthias T, Pfeiffer S, Selmi C, Eric Gershwin M. "Diagnostic challenges in celiac disease and the role of the tissue transglutaminase-neo-epitope". Clin Rev Allergy Immunol (Review) 2010; **38** (2–3): 298–301. [doi](https://en.wikipedia.org/wiki/Doi_%28identifier%29%22%20%5Co%20%22Doi%20%28identifier%29):[10.1007/s12016-009-8160-z](https://doi.org/10.1007/s12016-009-8160-z). [PMID](https://en.wikipedia.org/wiki/PMID_%28identifier%29%22%20%5Co%20%22PMID%20%28identifier%29) [19629760](https://pubmed.ncbi.nlm.nih.gov/19629760). [S2CID](https://en.wikipedia.org/wiki/S2CID_%28identifier%29%22%20%5Co%20%22S2CID%20%28identifier%29) [33661098](https://api.semanticscholar.org/CorpusID%3A33661098).

6- Molina-Infante J, Santolaria S, Sanders DS, Fernández-Bañares F. ["Systematic review: noncoeliac gluten sensitivity"](https://doi.org/10.1111/apt.13155). Alimentary Pharmacology & Therapeutics (Review) 2015; **41** (9): 807–20. [doi](https://en.wikipedia.org/wiki/Doi_%28identifier%29%22%20%5Co%20%22Doi%20%28identifier%29):[10.1111/apt.13155](https://doi.org/10.1111/apt.13155). [PMID](https://en.wikipedia.org/wiki/PMID_%28identifier%29%22%20%5Co%20%22PMID%20%28identifier%29) [25753138](https://pubmed.ncbi.nlm.nih.gov/25753138). [S2CID](https://en.wikipedia.org/wiki/S2CID_%28identifier%29%22%20%5Co%20%22S2CID%20%28identifier%29) [207050854](https://api.semanticscholar.org/CorpusID%3A207050854).

7- Ludvigsson JF, Card T, Ciclitira PJ, Swift GL, Nasr I, Sanders DS, Ciacci C. ["Support for patients with celiac disease: A literature review"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406900). United European Gastroenterology Journal (Review) 2015; **3** (2): 146–59.  [doi](https://en.wikipedia.org/wiki/Doi_%28identifier%29%22%20%5Co%20%22Doi%20%28identifier%29):[10.1177/2050640614562599](https://doi.org/10.1177/2050640614562599). [PMC](https://en.wikipedia.org/wiki/PMC_%28identifier%29%22%20%5Co%20%22PMC%20%28identifier%29) [4406900](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406900). [PMID](https://en.wikipedia.org/wiki/PMID_%28identifier%29%22%20%5Co%20%22PMID%20%28identifier%29) [25922674](https://pubmed.ncbi.nlm.nih.gov/25922674).

8- Burkhardt, J. G.; Chapa-Rodriguez, A.; Bahna, S. L.  ["Gluten sensitivities and the allergist: Threshing the grain from the husks"](https://doi.org/10.1111/all.13354). Allergy 2018; **73** (7): 1359–1368. [doi](https://en.wikipedia.org/wiki/Doi_%28identifier%29%22%20%5Co%20%22Doi%20%28identifier%29):[10.1111/all.13354](https://doi.org/10.1111/all.13354). [PMID](https://en.wikipedia.org/wiki/PMID_%28identifier%29%22%20%5Co%20%22PMID%20%28identifier%29) [29131356](https://pubmed.ncbi.nlm.nih.gov/29131356).

9-Othman, A., E. Alyosfi, and H. AL-Shamahy.“THE ASSOCIATION OF EPSTEIN-BARR VIRUS ANTIBODIES WITH RHEUMATOID ARTHRITIS AMONG YEMENI PATIENTS IN SANA’A CITY”. Universal Journal of Pharmaceutical Research, Vol. 2, no. 4, July 2017, doi:https://doi.org/10.22270/ujpr.v2i4.R4.

10-Othman, A., E. Hamzah, J. Almughales, and A. Al-Mikhlafy.“SERUM POSITIVITY OF ANA AND ASMA AMONG KHAT AND NONKHAT CHEWERS AS MARKERS FOR AUTOIMMUNE HEPATITIS TYPE 1”. Universal Journal of Pharmaceutical Research, Vol. 2, no. 4, July 2017, doi:https://doi.org/10.22270/ujpr.v2i4.R5.

11-Al-Anesi M, Hu Q, Al-Eryani E, Al-Amrani M, Al-Shamahy H. The association of adult male and female infertility with celiac disease patients in Yemen. Universal Journal of Pharmaceutical Research 2017; 2(6): 21-23. DOI: http://doi.org/10.22270/ujpr.v2i6.R5

12-El-Aghbary, D., A. Al-Jaaidi, K. Al-Moyed, A. A. Al-Robasi, and A. Othman.“SEROPREVALENCE OF ANTI-MANNOSE BINDING LECTIN AUTOANTIBODIES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SANA’A CITY- YEMEN”. Universal Journal of Pharmaceutical Research, Vol. 3, no. 2, May 2018, pp. 34-37, doi:https://doi.org/10.22270/ujpr.v3i2.138.

13-Al-Shamahy, H. A., and A. A. Ishak. “TRENDS AND CAUSES OF MORBIDITY IN PART OF CHILDREN IN THE CITY OF SANA’A, YEMEN 1978-2018: FINDINGS OF SINGLE CHILDREN’S HEALTH CENTER”. Universal Journal of Pharmaceutical Research, Vol. 5, no. 6, Jan. 2021, doi:https://doi.org/10.22270/ujpr.v5i6.504.

14-Shamsan, E. N. A., C. De-ping, H. A. Al-Shamahy, M. M. Ali Al- Hajj, J. Bo-fan, and Z. Yaogang. “COCCIDIAN INTESTINAL PARASITES AMONG CHILDREN IN AL-TORBAH CITY IN YEMEN: IN COUNTRY WITH HIGH INCIDENCE OF MALNUTRITION”. Universal Journal of Pharmaceutical Research, Vol. 4, no. 4, Sept. 2019, doi:https://doi.org/10.22270/ujpr.v4i4.301.

15-Sheiban, A., H. Al-Shamahy, N. Alattab, and A.-K.Abbas. “EPIDEMICITY OF VIBRIO CHOLERA IN SANA’A CITY, YEMEN: PREVALENCE AND POTENTIAL DETERMINANTS”. Universal Journal of Pharmaceutical Research, Vol. 2, no. 6, Nov. 2018, doi:https://doi.org/10.22270/ujpr.v2i6.R1.

16-Collin, P. [Rasmussen](https://pubmed.ncbi.nlm.nih.gov/?term=Rasmussen+M&cauthor_id=11861953) M, [Kyrönpalo](https://pubmed.ncbi.nlm.nih.gov/?term=Kyr%C3%B6npalo+S&cauthor_id=11861953) S *et al.,* The hunt for coeliac disease in primary care. Qjm, 2002. **95**(2):75-77. PMID: **11861953,** DOI: [10.1093/qjmed/95.2.75](https://doi.org/10.1093/qjmed/95.2.75%22%20%5Ct%20%22_blank)

17-Al Attas, R.A., How common is celiac disease in Eastern Saudi Arabia. Ann Saudi Med, 2002. **22**(5-6):315-319.doi: 10.5144/0256-4947.2002.315.

18-Sanders, D.S.,   [Patel](https://pubmed.ncbi.nlm.nih.gov/?term=Patel+D&cauthor_id=12655262) D,  [Stephenson](https://pubmed.ncbi.nlm.nih.gov/?term=Stephenson+TJ&cauthor_id=12655262) TJ *et al.,* A primary care cross-sectional study of undiagnosed adult coeliac disease. European journal of gastroenterology & hepatology, 2003. 15(4): p. 407-413. PMID: **12655262**, DOI: [10.1097/00042737-200304000-00012](https://doi.org/10.1097/00042737-200304000-00012%22%20%5Ct%20%22_blank)

19-Hadithi M, [Mary E von Blomberg](https://pubmed.ncbi.nlm.nih.gov/?term=von+Blomberg+BM&cauthor_id=17785484), [Crusius](https://pubmed.ncbi.nlm.nih.gov/?term=Crusius+JB&cauthor_id=17785484) JBA, *et al.,* Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. Annals of internal medicine, 2007. **147**(5): 294-302. PMID: **17785484**, DOI: [10.7326/0003-4819-147-5-200709040-00003](https://doi.org/10.7326/0003-4819-147-5-200709040-00003%22%20%5Ct%20%22_blank)

20-Catassi, C., [Kryszak](https://pubmed.ncbi.nlm.nih.gov/?term=Kryszak+D&cauthor_id=17355413) D,  [Louis-Jacques](https://pubmed.ncbi.nlm.nih.gov/?term=Louis-Jacques+O&cauthor_id=17355413) O, *et al.,* Detection of celiac disease in primary care: a multicenter case-finding study in North America. The American journal of gastroenterology, 2007. **102**(7):1454. PMID: **17355413,** DOI: [10.1111/j.1572-0241.2007.01173.x](https://doi.org/10.1111/j.1572-0241.2007.01173.x%22%20%5Ct%20%22_blank)

21-Dickey, W., S. McMillan, and D. Hughes, Identification of coeliac disease in primary care. Scandinavian journal of gastroenterology, 1998. **33**(5): 491-493.

22-Hopper, A.D., *et al.,* Pre-endoscopy serological testing for coeliac disease: evaluation of a clinical decision tool. Bmj, 2007. **334**(7596): 729.

23-Shahbazkhani, B., *et al.,* Coeliac disease presenting with symptoms of irritable bowel syndrome. Alimentary pharmacology & therapeutics, 2003. **18**(2):231-235.

24-Carroccio, A., *et al*., Comparison of anti-transglutaminase ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: a prospective study. Clinical chemistry, 2002. **48**(9): p. 1546-1550.

25-King JA, Jeong J, Underwood FE, *et al.* Incidence of celiac disease is increasing over time: a systematic review and meta-analysis. Am J Gastroenterol 2020; 115:507–525.

26- Jansson-Knodell CL, Hujoel IA, West CP*, et al.* Sex difference in celiac disease in undiagnosed populations: a systematic review and meta-analysis. ClinGastroenterolHepatol 2019;17:1954–1968.

27- Rubio-Tapia A, Kyle RA, Kaplan EL, *et al.* Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009;137:88–93.

28- Katz KD, Rashtak S, Lahr BD, *et al.* Screening for celiacdisease in a North American population: sequential serology and gastrointestinal symptoms. Am J Gastroenterol 2011;106:1333–1339.

29- Lebwohl B, Tennyson CA, Holub JL, *et al.* Sex and racial disparities in duodenal biopsy to evaluate for celiac disease. GastrointestEndosc 2012;76:779–785.

30- Collin P, Vilppula A, Luostarinen L, *et al.* Review article: coeliac disease in later life must not be missed. Aliment PharmacolTher 2018;47:563–572.

31- Catassi C, Kryszak D, Bhatti B, *et al.* Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med 2010;42:530–538.

32- Liu E, Dong F, Barón AE, *et al.* High incidence of celiac disease in a long-term study of adolescents with susceptibility genotypes. Gastroenterology 2017;152:1329–1336.

33- AndrénAronsson C, Lee H-S, HårdAfSegerstad EM, *et al*. Association of gluten intake during the first 5 years of life with incidence of celiac disease autoimmunity and celiac disease among children at increased risk. JAMA 2019;322(6):514–523.

34-Fasano, A. and C. Catassi, Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology, 2001. **120**(3): p. 636-651.

35-Lasa, J., *et al.,* Iron-deficiency anemia as a subclinical celiac disease presentation in an Argentinian population. Revista de Gastroenterología de México (English Edition), 2017. **82**(3): 270-273.

36-Daya, H.A., *et al.,* Celiac disease patients presenting with anemia have more severe disease than those presenting with diarrhea. Clinical Gastroenterology and Hepatology, 2013. **11**(11):1472-1477.

37-Lo W, Sano K, Lebwohl B, *et al.* Changing presentation of adult celiac disease. Dig Dis Sci 2003;48:395-398.

38- Lebwohl B, Roy A, Alaedini A, *et al.* Risk of headacherelated healthcare visits in patients with celiac disease: a population-based observational study. Headache 2016;56:849-858.

39- Zingone F, Swift GL, Card TR, *et al.* Psychological morbidity of celiac disease: a review of the literature. United European Gastroenterol J 2015;3:136-145.

40- Castillo NE, Vanga RR, Theethira TG, et al. Prevalence of abnormal liver function tests in celiac disease and the effect of a gluten-free diet in the US population. Am J Gastroenterol 2015;110:1216-222.

41- Ludvigsson JF, Leffler DA, Bai JC, *et al.*The Oslo definitions for coeliac disease and related terms. Gut 2013; 62:43-52.

42- Green P, Stavropoulos S, Panagi SG, Goldstein S. Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol 2001;96:126-131.

43- Sanders DS. Changing face of adult coeliac disease: experience of a single university hospital in South Yorkshire. Postgrad Med J 2002;78(915):31-33.

Table 1: Age and gender distribution of patients with intestinal symptoms admitted to University of Science and Technology Hospital, Sana'a, Yemen - during the period from March 2014 to December 2018

|  |  |  |  |
| --- | --- | --- | --- |
| Characters | Number | % | P |
| **Gender** |
| Male | 245 | 40.8 | <0.05 |
| Female | 355 | 59.2 |
| **Age groups** |
| 2-19 years | 126 | 21 | <0.05 |
| 20-40 years | 349 | 58.2 |
| 41-60 years | 108 | 18 |
| >60 years | 17 | 2.8 |
| Total | 600 | 100 | Mean ±SD =30±14.5 years |

\*significance level less than 0.05 (P).

Table 2: Prevalence of Serological Markers; Anti-tissue IgA glutaminase and small bowel biopsies for celiac disease among different sex and age groups of patients with intestinal symptoms

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Characters** | celiac disease n=55 | **OR** | **CI 95%** | **X2** | **p** |
| No | % |
| **Gender** |
| Male n=245 | 15 | 6.1 | 0.5 | 0.2-0.9 | 4.6 | 0.03 |
| Female n=355 | 40 | 11.3 | 1.9 | 1.1-3.6 | 4.6 | 0.03 |
| **Age groups** |
| 2-19 years n=126 | 27 | 21.4 | 4.3 | 2.4-7.6 | 28.8 | <0.001 |
| 20-40 years n=349 | 23 | 6.6 | 0.4 | 0.2-0.8 | 6.6 | 0.009 |
| 41-60 years n=108 | 5 | 4.6 | 0.4 | 0.16-1.1 | 3.2 | 0.07 |
| >60 years n=17 | 0 | 0 | 00 | 0-1.9 | 1.7 | 0.18 |
| Total n=600 | 55 | 9.2 |  |  |  |  |

Table 3: Clinical signs and symptoms associated with intestinal symptoms compared to celiac disease patients admitted to University of Science and Technology hospitals, Sana'a, Yemen - during the period from March 2014 to December 2018

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Symptoms and signs** | Patients with intestinal symptoms  **n=545** | **celiac disease n=55** | **OR** | ***CI* 95%** | ***X2*** | ***p*** |
| No | % | % | No |
| Chronic diarrhea  | 223 | 40.9 | 51 | 92.7 | 18.4 | 6.6-56 | 54 | <0.001 |
| Steatorrhoea  | 278 | 51 | 50 | 90.9 | 9.6 | 3.7-24.5 | 32 | <0.001 |
| Foul odor | 191 | 35 | 45 | 81.8 | 8.3 | 4.1-16.9 | 45 | <0.001 |
| Weight loss | 376 | 68.9 | 51 | 92.7 | 5.7 | 2-16.1 | 13.7 | <0.001 |
| Fatigue | 321 | 58.9 | 39 | 70.9 | 1.7 | 0.9-3.1 | 3 | 0.08 |
| Anemia | 31 | 5.7 | 39 | 70.9 | 40.4 | 20.3-80.2 | 206 | <0.001 |
| Abdominal pain | 447 | 82.2 | 49 | 89 | 1.8 | 0.7-4.2 | 1.7 | 0.18 |
| Cramping | 387 | 71 | 41 | 74.5 | 1.2 | 0.6-2.1 | 0.3 | 0.55 |
| Abdominal distension | 277 | 50.8 | 42 | 76.4 | 3.1 | 1.6-5.9 | 13 | <0.001 |
| Mouth ulcers | 9 | 1.7 | 6 | 10.9 | 7.2 | 2.5-21 | 17.5 | <0.001 |
| Irritable bowel syndrome | 169 | 31 | 3 | 5.5 | 0.12 | 0.03-0.4 | 15.9 | <0.001 |
| Abdominal bleeding | 11 | 2.02 | 12 | 21.8 | 13.5 | 5.6-32.5 | 53.1 | <0.001 |
| Abnormal LFT | 114 | 20.9 | 11 | 20 | 0.9 | 0.4-1.8 | 0.02 | 0.87 |
| Diabetes mellitus I | 3 | 0.55 | 5 | 9 | 18 | 4.1-77.8 | 27.6 | <0.001 |
| Hypothyroidism | 1 | 0.18 | 7 | 12.7 | 79.3 | 9.5-658 | 59.7 | <0.001 |